ProteinQure’s Post

View organization page for ProteinQure, graphic

5,791 followers

View profile for Lucas Siow, graphic

CoFounder at ProteinQure - Dare to Deliver

🚀 Big News from ProteinQure! 🚀 Exciting update: ProteinQure, has validated our lead program for triple-negative breast cancer (TNBC) and I'm thrilled to announce that our findings will be presented at the upcoming AACR conference in San Diego, showcasing our commitment to advancing cancer research (see press release for poster details). Our novel Peptide Drug Conjugate (PDC) has shown exceptional efficacy in battling TNBC, even in treatment-resistant cases. Performed at Dr. David Cescon's lab at Princess Margaret Cancer Centre/University Health Network, our PDC demonstrated remarkable results in over 15 heterogeneous Patient-Derived Xenograft (PDX) models. As a computational drug discovery company, it has been amazing to stop trying to convince people with benchmarks on irrelevant data sets and start pointing to multiple drug candidates that ProteinQure has enabled. We are looking forward to collaborating further with world-class clinicians on our Phase I clinical trial in the near future. I will be at AACR to learn from and speak to researchers about our development candidate and planned FIH trial. #ProteinQure #CancerResearch #AACR2024 #PrecisionMedicine #DrugDevelopment #AIDrugDiscovery https://lnkd.in/geZTFMtY

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

accesswire.com

Ian McLean

Software Developer | UBC Instructor | Dormant Biologist

7mo

Love this!

David Tart

Business Development Manager, Emerging Biopharma, R&D Solutions at IQVIA Biotech

7mo

Congrats Lucas!

See more comments

To view or add a comment, sign in

Explore topics